VivoSeq
Other

Coagulopathy

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Coagulopathy is an early-stage landscape with 0 programs across 1 company. The most active players are CSL Behring.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

85/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

CSL Behring logo

CSL Behring

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Completed11 · 69%
Not yet recruiting2 · 13%
Unknown status1 · 6%
Terminated1 · 6%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

16 trials

Pre-hospital Administration of Fibrinogen in Trauma-Induced Coagulopathy
Not yet recruiting·UUnidade Local de Saude do Arco Ribeirinho·N/A·NCT06582420·52 enrolled
Role of Fibrinolytic Activity in Neoplastic Pathologies Complicated by Coagulopathy
Not yet recruiting·UUniversity Hospital, Strasbourg, France·N/A·NCT07234630·150 enrolled
RAS and Coagulopathy in COVID19
Completed·IImperial College London·Phase 1·NCT04419610·28 enrolled
Pre-hospital Administration of Lyophilized Plasma for Post-traumatic Coagulopathy Treatment (PREHO-PLYO)
Completed·FFrench Defence Health Service·Phase 3·NCT02736812·140 enrolled
An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure
Completed·CSL Behring logoCSL Behring·Phase 3·NCT00803101·176 enrolled
TEG (Thromboelastography) Based Versus Conventional Coagulation Parameters Based Correction of Coagulopathy in Non Variceal Bleed.
Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02689232·96 enrolled
Prevention of Cefoperazone-induced Coagulopathy
Completed·HHelwan University·Phase 4·NCT05742295·56 enrolled
Oral Vitamin K for Warfarin Associated Coagulopathy
Completed·SSt. Joseph's Healthcare Hamilton·Phase 3·NCT00143715·690 enrolled
Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)
Completed·MMonash University·Phase 3·NCT02187120·1,310 enrolled
Freeze-dried Plasma in the Initial Management of Coagulopathy in Trauma Patients
Completed·UUniversity Hospital, Lille·Phase 3·NCT02750150·42 enrolled
Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects
Completed·CSL Behring logoCSL Behring·Phase 3·NCT02281201·11 enrolled
Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study.
Completed·UUniversity Children's Hospital, Zurich·Phase 4·NCT01487837·57 enrolled
Dilutional Coagulopathy in Patients Undergoing Elective Surgery
Completed·—·Phase 1/2·NCT00493272·20 enrolled
Comparison of the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy
Terminated·EEntegrion, Inc.·Phase 2·NCT03700723·4 enrolled
Assessment of Artificial Intelligence Algorithms for ROTEM Analysis in Coagulation Management
Withdrawn·OOndokuz Mayıs University·N/A·NCT07043556
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)